Incyte (INCY) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
The company's earnings beat estimates in two of the trailing four quarters and missed the same in the other two, delivering an average negative surprise of 13.54%. In the last reported quarter, Incyte delivered a negative earnings surprise of 12.40%. Let's see how things might have shaped up prior to the announcement. Factors to Consider Incyte primarily derives product revenues from sales of its lead drug, Jakafi (ruxolitinib), in the United States and other marketed drugs. An increase in the sales of Jakafi, a first-in-class JAK1/JAK2 inhibitor in all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]), is likely to have boosted revenues in the first quarter. However, competition from other approved drugs might have inhibited sales growth potential to some extent. The Zacks Consensus Estimate for Jakafi's sales in first-quarter 2024 is pegged at $642.2 million. Incyte earns product royalty revenues from Novartis
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Incyte to Present at Upcoming Investor ConferenceBusiness Wire
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at TD Cowen from $88.00 to $80.00. They now have a "buy" rating on the stock.MarketBeat
- Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $83.00 price target on the stock, down previously from $84.00.MarketBeat
INCY
Earnings
- 4/30/24 - Miss
INCY
Sec Filings
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- 4/29/24 - Form ARS
- INCY's page on the SEC website